Leveraging Metabolomics to Assess the Next Generation of Temozolomide-based Therapeutic Approaches for Glioblastomas

查看全文 作　　者：Patrick-Denis St-[1]Coeur;Mohamed [1]Touaibia;Miroslava Cuperlovic-[2]Culf;Pier Jr [1]Morin

机构地区：[1]Department of Chemistry and Biochemistry, Universite' de Moncton,Moncton, NBE1A3E9, Canada;[2]National Research Council of Canada,Moncton, NBE1A7R1, Canada

出　　处：《Genomics, Proteomics & Bioinformatics》索引2013年第11卷第4期,共8页

基　　金：the Beatrice Hunter Cancer Research Institute;the Brain Tumour Foundation of Canada 摘　　要：Glioblastoma multiforme(GBM) is the most common adult primary tumor of the central nervous system.The current standard of care for glioblastoma patients involves a combination of surgery,radiotherapy and chemotherapy with the alkylating agent temozolomide.Several mechanisms underlying the inherent and acquired temozolomide resistance have been identifed and contribute to treatment failure.Early identifcation of temozolomide-resistant GBM patients and improvement of the therapeutic strategies available to treat this malignancy are of uttermost importance.This review initially looks at the molecular pathways underlying GBM formation and development with a particular emphasis placed on recent therapeutic advances made in the feld.Our focus will next be directed toward the molecular mechanisms modulating temozolomide resistance in GBM patients and the strategies envisioned to circumvent this resistance.Finally,we highlight the diagnostic and prognostic value of metabolomics in cancers and assess its potential usefulness in improving the current standard of care for GBM patients. 关键词：神经胶质瘤替莫唑胺代谢组学治疗评估分子机制恶性肿瘤神经系统

相关文献

参考文献（98）
引证文献（5）
耦合文献（54）

参考文献(98)

引证文献(5)

耦合文献(54)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Leveraging Metabolomics to Assess the Next Generation of Temozolomide-based Therapeutic Approaches for Glioblastomas

参考文献(98)

引证文献(5)

耦合文献(54)

用户提示